Sensus Healthcare (NASDAQ:SRTS) Given New $8.00 Price Target at HC Wainwright

Sensus Healthcare (NASDAQ:SRTS) had its price objective dropped by equities researchers at HC Wainwright from $12.00 to $8.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 133.92% from the stock’s current price. HC Wainwright also issued estimates for Sensus Healthcare’s Q2 2026 earnings at ($0.01) EPS.

Several other research analysts also recently weighed in on SRTS. Maxim Group lowered their target price on Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Lake Street Capital lowered their target price on Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a research note on Sunday, June 22nd.

Sensus Healthcare Stock Up 4.6%

NASDAQ:SRTS opened at $3.42 on Tuesday. The stock’s 50 day moving average price is $4.75 and its 200 day moving average price is $4.93. Sensus Healthcare has a 52-week low of $3.03 and a 52-week high of $9.33. The company has a market capitalization of $56.22 million, a PE ratio of -57.00 and a beta of 1.34.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.07). Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.56%. The company had revenue of $7.32 million during the quarter, compared to analysts’ expectations of $9.30 million. As a group, sell-side analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently modified their holdings of the business. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Sensus Healthcare in the second quarter valued at approximately $3,170,000. Acadian Asset Management LLC boosted its stake in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock valued at $2,225,000 after buying an additional 122,746 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Sensus Healthcare by 5.3% in the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company’s stock valued at $2,982,000 after buying an additional 21,600 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Sensus Healthcare by 30.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after buying an additional 88,953 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Sensus Healthcare by 2.5% during the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after purchasing an additional 3,766 shares during the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.